MDS-ALLO-RISK: Allogeneic hematopoietic stem cell transplantation in patients with low or intermediate-1 risk myelodysplastic syndrome

A prospective multicenter phase II study based on donor availability on behalf of the GFM & SFGM-TC
Promotor : Groupe Francophone des Myélodysplasies (GFM)
Coordinators :  Marie Robin, PhD, Marie Sébert, PhD
Investigators CentersI from the French MDS Group (see list of centers) and centers from the European community

• Télécharger le protocole